IBDEI0MU ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,11182,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,11183,0)
 ;;=204.11^^64^694^18
 ;;^UTILITY(U,$J,358.3,11183,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11183,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,11183,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,11183,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,11184,0)
 ;;=201.90^^64^694^83
 ;;^UTILITY(U,$J,358.3,11184,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11184,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,11184,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,11184,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,11185,0)
 ;;=785.6^^64^694^89
 ;;^UTILITY(U,$J,358.3,11185,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11185,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,11185,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,11185,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,11186,0)
 ;;=200.20^^64^694^90
 ;;^UTILITY(U,$J,358.3,11186,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11186,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,11186,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,11186,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,11187,0)
 ;;=202.00^^64^694^92
 ;;^UTILITY(U,$J,358.3,11187,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11187,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,11187,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,11187,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,11188,0)
 ;;=200.10^^64^694^91
 ;;^UTILITY(U,$J,358.3,11188,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11188,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,11188,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,11188,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,11189,0)
 ;;=273.3^^64^694^93
 ;;^UTILITY(U,$J,358.3,11189,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11189,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,11189,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,11189,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,11190,0)
 ;;=203.00^^64^694^103
 ;;^UTILITY(U,$J,358.3,11190,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11190,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,11190,1,5,0)
 ;;=5^Multiple Myeloma w/o Remission
 ;;^UTILITY(U,$J,358.3,11190,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,11191,0)
 ;;=203.01^^64^694^105
 ;;^UTILITY(U,$J,358.3,11191,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11191,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,11191,1,5,0)
 ;;=5^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,11191,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,11192,0)
 ;;=238.6^^64^694^108
 ;;^UTILITY(U,$J,358.3,11192,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11192,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,11192,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,11192,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,11193,0)
 ;;=205.00^^64^694^4
 ;;^UTILITY(U,$J,358.3,11193,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11193,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,11193,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,11193,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,11194,0)
 ;;=205.01^^64^694^6
 ;;^UTILITY(U,$J,358.3,11194,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11194,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,11194,1,5,0)
 ;;=5^AML,In Remission
 ;;^UTILITY(U,$J,358.3,11194,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,11195,0)
 ;;=205.10^^64^694^19
 ;;^UTILITY(U,$J,358.3,11195,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,11195,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,11195,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,11195,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,11196,0)
 ;;=205.11^^64^694^21
 ;;^UTILITY(U,$J,358.3,11196,1,0)
 ;;=^358.31IA^5^2
